A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report in the Oct. 28 issue of the New England Journal of Medicine (NEJM).A second patient who had a similar tumor that was not fueled by the mutant protein, called ALK (named for the first…
Continue